EUVIMEDOpdag EUVIMED
Open access

Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies

Amanda E Marinoff iD, Kathryn Aaronson, Anurag K Agrawal iD, Benjamin S Braun iD, Carla Golden, Benjamin J Huang, Jennifer Michlitsch, Erica Southworth, Allyson Thrall, Kieuhoa T Vo iD, Elliot Stieglitz iD

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30335 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2023. Written by Amanda E Marinoff and 10 co-authors. Institution: Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, San Francisco, CA, USA. Major MEDLINE topics: Leukemia, Myeloid, Acute, Hematologic Neoplasms. Cited 15 times so far (Crossref); 27 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, National Institutes of Health, Alex's Lemonade Stand Foundation for Childhood Cancer.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Venetoclax is frequently used as salvage treatment in pediatric, adolescent, and young adult (AYA) patients with advanced hematologic malignancies. However, more data are needed from real‐world studies to guide the safe and appropriate use of venetoclax in this population. Procedure We retrospectively reviewed the medical records of all patients diagnosed with hematologic malignancies less than 30 years of age treated with venetoclax outside of clinical trials at the University of California San Francisco Benioff Children's Hospitals from 2016 to 2022.

Results

We identified 13 patients (acute myeloid leukemia , n = 8; B‐acute lymphoblastic leukemia, n = 3; myelodysplastic syndrome, n = 2) aged 4 months to 27 years. A median of 3 prior lines of therapy weregiven (range 0–5). All patients received venetoclax in combination with either a hypomethylating agent or conventional chemotherapy. Three (23%) patients achieved complete remission (CR); two (15%) achieved partial remission (PR); 3 (23%) had stable disease (SD), and five (42%) had progressive disease. Median survival and time to progression from venetoclax initiation was 9 months (range 2.5–52 months) and 3 months (range 2 weeks to 7.5 months), respectively. Six patients (46%) developed grade 3 or higher infections while receiving venetoclax, including bacteremia due to atypical organisms, invasive pulmonary infections with Aspergillus, cytomegalovirus (CMV) viremia, skin infections, and encephalitis with bacterial brain abscesses.

Conclusions

Venetoclax in combination with hypomethylating agents or cytotoxic chemotherapy was effective in a subset of pediatric/AYA patients with advanced hematologic malignancies, but multiple severe infections were observed, particularly among patients who received venetoclax in combination with chemotherapy. Prospective studies will be required to determine the optimal dose and duration of venetoclax in this population.

Subjects

MeSH terms (MEDLINE)

Leukemia, Myeloid, AcuteHematologic NeoplasmsAdolescentYoung AdultHumansChildAdultRetrospective StudiesProspective StudiesBridged Bicyclo Compounds, HeterocyclicAntineoplastic Combined Chemotherapy ProtocolsSulfonamides

Author keywords

adolescent and young adultsinfectionleukemiapediatricvenetoclax

Substances

Bridged Bicyclo Compounds, HeterocyclicvenetoclaxSulfonamides

Authors and institutions

  • Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, San Francisco, CA, USA.

ORCID profiles: Amanda E Marinoff, Anurag K Agrawal, Benjamin S Braun, Kieuhoa T Vo, Elliot Stieglitz

Funding

  • NCI NIH HHS
  • National Institutes of Health
  • Alex's Lemonade Stand Foundation for Childhood Cancer

Cite

APA

Marinoff, A. E., Aaronson, K., Agrawal, A. K., Braun, B. S., Golden, C., Huang, B. J., Michlitsch, J., Southworth, E., Thrall, A., Vo, K. T., & Stieglitz, E. (2023). Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30335

Vancouver

Marinoff AE, Aaronson K, Agrawal AK, Braun BS, Golden C, Huang BJ, et al. Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30335

BibTeX
@article{Marinoff2023,
  author = {Marinoff, Amanda E and Aaronson, Kathryn and Agrawal, Anurag K and Braun, Benjamin S and Golden, Carla and Huang, Benjamin J and Michlitsch, Jennifer and Southworth, Erica and Thrall, Allyson and Vo, Kieuhoa T and Stieglitz, Elliot},
  title = {Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30335}
}
Start for free →